Bioharvest Sciences (BHST) Common Equity (2023 - 2025)

Bioharvest Sciences' Common Equity history runs 3 years deep, the most recent figure standing at $25.4 million for Q4 2025.

• On a quarterly basis, Common Equity rose 1813.38% year-over-year to $25.4 million in Q4 2025; TTM through Dec 2025 was $25.4 million, a 1813.38% increase from a year earlier, with the FY2025 full-year figure at $25.4 million, up 1813.38% from the prior year.
• Common Equity grew to $25.4 million in Q4 2025 per BHST's latest filing, from $7.7 million in the prior quarter.
• Across five years, Common Equity topped out at $25.4 million in Q4 2025 and bottomed at -$83.5 million in Q4 2023.
• The 3-year median for Common Equity is $1.3 million (2024), against an average of -$4.7 million.
• Biggest YoY gain for Common Equity was 1813.38% in 2025; the steepest drop was 165.86% in 2025.
• Year by year, Common Equity stood at -$83.5 million in 2023, then jumped by 101.59% to $1.3 million in 2024, then surged by 1813.38% to $25.4 million in 2025.
• Per Business Quant, the three latest BHST Common Equity figures stand at $25.4 million (Q4 2025), $7.7 million (Q3 2025), and -$4.2 million (Q2 2025).